Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1401Other hematologic neoplasm 431Myeloid 34Plasma cell 29Sarcoma 27Dermatologic 15CNS 12Classical hematology 9Tumor-Agnostic 4Thoracic 4Breast 4Head & Neck 3Genitourinary 3Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Other neoplasm 1Other 1

Conditions

Precancerous Conditions 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Cyclophosphamide 13Biopsy 13fludarabine phosphate 9Whole-Body Irradiation 9Surveys and Questionnaires 9Peripheral Blood Stem Cell Transplantation 9Busulfan 9Polymerase Chain Reaction 7Mycophenolic Acid 7Early Intervention, Educational 7Tacrolimus 6Gene Expression Profiling 6Educational Status 6Colposcopy 6Carboplatin 6fludarabine 5Paclitaxel 5Microarray Analysis 5Methotrexate 5Methods 5Melphalan 5Immunohistochemistry 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rituximab × Other neoplasm × Clear all
NCT00588822 2014-05-06

Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy of Undetermined Significance

Mayo Clinic

Phase 2 Terminated
21 enrolled 11 charts
Other neoplasm

Monoclonal Gammopathy of Undetermined Significance, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡